Short answer
Edwards Lifesciences (EW) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1.6B (up 16.7% year over year) with net income of $381M.
Q1 2026 key financials · XBRL
- Revenue
- $1.6B
- +16.7% YoY
- Net income
- $381M
- +6.3% YoY
- Operating margin
- 29.0%
- Gross margin
- 78.0%
- EPS (diluted)
- $0.66
- +8.2% YoY
Source: XBRL data from the Edwards Lifesciences (EW) Q1 2026 10-Q on SEC EDGAR. USD.
Edwards Lifesciences Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Risks cited: innovation, competition, reimbursement, cybersecurity, international operations, and Critical Care product-group sale
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Carried-forward risks remain the company’s principal operational, competitive, market, regulatory, and financial exposures
- February 2026 $500.0 million accelerated share repurchase reduced remaining authorization to $1,493.7 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edwards Lifesciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.